生脉膨化胶囊对心血管疾病及免疫调节影响的实验研究
|
摘要
目的：生脉膨化胶囊是红参经膨化提取后研制出的新型胶囊制剂。观察生脉膨化胶囊对免疫抑制、心肌缺氧、心气虚小鼠及慢性心力衰竭大鼠的保护作用,研究其对心血管疾病及免疫调节的影响。
方法：建立小鼠心气虚动物模型,检测小鼠心肌匀浆中超氧化物歧化酶(SOD)、丙二醛(MDA)、乳酸脱氢酶(LDH)、肌酸激酶(CK)含量；建立小鼠心肌缺氧动物模型,观察小鼠气管夹闭心电消失时间,特异性密闭耐缺氧小鼠存活时间；建立大鼠慢性心力衰竭动物模型,检测心脏重量指数(HW/BW)、左心室重量指数(LVW/BW)及血流动力学参数；建立小鼠免疫力低下动物模型,检测脏器指数、ConA诱导的小鼠脾淋巴细胞增值能力及骨髓DNA含量。
结果：(1)生脉膨化胶囊可明显提高心气虚小鼠心肌匀浆中SOD活性,尤以生脉膨化胶囊中剂量组最为显著(P<0.01)；可显著降低MDA含量,且中剂量组效果明显优于传统生脉胶囊组(P<0.01)；能够显著降低心气虚小鼠心肌匀浆中CK, LDH酶活性(P<0.01),降低LDH的效果显著优于传统生脉胶囊(P<0.05)。
(2)生脉膨化胶囊各剂量组脏器指数均高于正常组,中剂量组胸腺、脾脏、肾脏指数明显高于正常组(P<0.01),肝脏指数高于正常组(P<0.05)；高中剂量组能显著提升免疫抑制小鼠的淋巴细胞增值反应(P<0.01)；各剂量组DNA含量明显高于模型组(P<0.01),高剂量组高于传统生脉胶囊组。
(3)传统生脉胶囊组及膨化胶囊各剂量组均可延长小鼠气管夹闭心电消失时间(P<0.01),且膨化胶囊各剂量组效果优于传统生脉胶囊组(P<0.05),高剂量组优于中低剂量组。膨化胶囊高中剂量组均可明显延长密闭耐缺氧小鼠存活时间(P<0.05),且效果显著优于传统生脉胶囊(P<0.05)。
(4)生脉膨化胶囊能明显改善模型大鼠心衰症状、降低左心室指数(LVMI),减轻其组织病理性损害。生脉膨化胶囊治疗后均能明显升高±dp/dtmax及LVSP,并能明显降低LVEDP。
结论：生脉膨化胶囊对心气虚小鼠具有保护作用,对环磷酰胺引起的免疫器官及主要脏器的变化、脾脏功能下降及骨髓损伤具有一定的保护和恢复作用；可延长小鼠平均存活时间,降低心肌耗氧量,具有显著的抗心肌缺氧作用；能改善慢性心力衰竭左心收缩和舒张功能,具有抗慢性心力衰竭的疗效；生脉膨化胶囊药效优于传统生脉胶囊。
Objective:Expanded Sheng-mai Capsule is a new type of preparation with expanded red ginseng for processing. Observed the protective effect on immunosuppression,myocardial hypoxia,Heart-Qi Deficiency and chronic heart failure in rats. Studied the influence of cardioascular disease and immunoregulation on Expanded Sheng-mai Capsule.
Method:Established the animal models of Heart-Qi Deficiency in mice,detected the content of SOD、MDA、LDH and CK in myocardial extracts.Established the animal models of myocardial hypoxia in mice,the clipping trachea time,disappearance time of ECG,and survival time in specific closed hypoxia tolerance of mice were observed.Established the animal models of chronic heart failure in rats,detected HW/BW、LVW/BW and hemodynamic parameters.Established the animal models of low immunity in mice,detected the viscera index、the spleen T lymphocyte reproductive activity induced by ConA and DNA content of marrow.
Result:(1) Expanded Sheng-mai Capsule can obviously improve SOD activity in myocardial extracts of mice,especially the middle dose group (P<0.01);the efforts of MDA reduction in the middle dose group is superior to the traditional Sheng-mai Capsule(P<0.01);CK,LDH enzyme activity were significantly decreased in Heart-Qi Deficiency mice,the reduction of LDH is superior to the Traditional Sheng-mai Capsule (P<0.05).
(2)the viscera index in different dose groups of Expanded Sheng-mai Capsule were all higher than control group,the thymus index、spleen index and renal index of middle dose group were obviously superior to that of control group (P<0.01),the liver index was higher than control group (P<0.05).The high dose group and middle dose group could significantly raise cell proliferative responses of immunosuppression in mice (P<0.01);DNA content in different dose groups were much higher than model group (P<0.01),the high dose group was higher than Traditional Sheng-mai Capsule.
(3) Expanded Sheng-mai Capsule and Traditional Sheng-mai Capsule could both prolong the clipping trachea time and disappearance time of ECG (P<0.01),different dose groups of Expanded Sheng-mai Capsule were all better than Traditional Sheng-mai Capsule (P<0.05),the efforts of high dose group was much better than the middle dose group and low dose group.The high dose group and middle dose group of Expanded Sheng-mai Capsule could obviously prolong the survival time in closed hypoxia tolerance of mice (P<0.05),and were much better than that of Traditional Sheng-mai Capsule (P<0.05).
(4) Expanded Shengmai capsules could obviously improve the symptoms of heart failure in rats,decrease LVMI,reduce its organization pathological injury.Expanded Sheng-mai Capsules treatment can obviously increase±dp/dtmax and LVSP,and decrease LVEDP obviously.
Conelusion:Expanded Sheng-mai Capsules could protect Heart-Qi Deficiency in mice,it may play a role in protect and recover change in immune organs and main organs、the changes of spleen function and bone marrow injury caused by cyclophosphamide,the mean survival time of mice was prolonged,decrease myocardial oxygen consumption.It has remarkable effect to myocardium against hypoxia.Expanded Sheng-mai Capsules may improve CHF systolic and diastolic function of the left ventricular,and has the efficacy of anti-CHF.The efficacy of Expanded Sheng-mai Capsules is better than Traditional Sheng-mai Capsule.
方法：建立小鼠心气虚动物模型,检测小鼠心肌匀浆中超氧化物歧化酶(SOD)、丙二醛(MDA)、乳酸脱氢酶(LDH)、肌酸激酶(CK)含量；建立小鼠心肌缺氧动物模型,观察小鼠气管夹闭心电消失时间,特异性密闭耐缺氧小鼠存活时间；建立大鼠慢性心力衰竭动物模型,检测心脏重量指数(HW/BW)、左心室重量指数(LVW/BW)及血流动力学参数；建立小鼠免疫力低下动物模型,检测脏器指数、ConA诱导的小鼠脾淋巴细胞增值能力及骨髓DNA含量。
结果：(1)生脉膨化胶囊可明显提高心气虚小鼠心肌匀浆中SOD活性,尤以生脉膨化胶囊中剂量组最为显著(P<0.01)；可显著降低MDA含量,且中剂量组效果明显优于传统生脉胶囊组(P<0.01)；能够显著降低心气虚小鼠心肌匀浆中CK, LDH酶活性(P<0.01),降低LDH的效果显著优于传统生脉胶囊(P<0.05)。
(2)生脉膨化胶囊各剂量组脏器指数均高于正常组,中剂量组胸腺、脾脏、肾脏指数明显高于正常组(P<0.01),肝脏指数高于正常组(P<0.05)；高中剂量组能显著提升免疫抑制小鼠的淋巴细胞增值反应(P<0.01)；各剂量组DNA含量明显高于模型组(P<0.01),高剂量组高于传统生脉胶囊组。
(3)传统生脉胶囊组及膨化胶囊各剂量组均可延长小鼠气管夹闭心电消失时间(P<0.01),且膨化胶囊各剂量组效果优于传统生脉胶囊组(P<0.05),高剂量组优于中低剂量组。膨化胶囊高中剂量组均可明显延长密闭耐缺氧小鼠存活时间(P<0.05),且效果显著优于传统生脉胶囊(P<0.05)。
(4)生脉膨化胶囊能明显改善模型大鼠心衰症状、降低左心室指数(LVMI),减轻其组织病理性损害。生脉膨化胶囊治疗后均能明显升高±dp/dtmax及LVSP,并能明显降低LVEDP。
结论：生脉膨化胶囊对心气虚小鼠具有保护作用,对环磷酰胺引起的免疫器官及主要脏器的变化、脾脏功能下降及骨髓损伤具有一定的保护和恢复作用；可延长小鼠平均存活时间,降低心肌耗氧量,具有显著的抗心肌缺氧作用；能改善慢性心力衰竭左心收缩和舒张功能,具有抗慢性心力衰竭的疗效；生脉膨化胶囊药效优于传统生脉胶囊。
Objective:Expanded Sheng-mai Capsule is a new type of preparation with expanded red ginseng for processing. Observed the protective effect on immunosuppression,myocardial hypoxia,Heart-Qi Deficiency and chronic heart failure in rats. Studied the influence of cardioascular disease and immunoregulation on Expanded Sheng-mai Capsule.
Method:Established the animal models of Heart-Qi Deficiency in mice,detected the content of SOD、MDA、LDH and CK in myocardial extracts.Established the animal models of myocardial hypoxia in mice,the clipping trachea time,disappearance time of ECG,and survival time in specific closed hypoxia tolerance of mice were observed.Established the animal models of chronic heart failure in rats,detected HW/BW、LVW/BW and hemodynamic parameters.Established the animal models of low immunity in mice,detected the viscera index、the spleen T lymphocyte reproductive activity induced by ConA and DNA content of marrow.
Result:(1) Expanded Sheng-mai Capsule can obviously improve SOD activity in myocardial extracts of mice,especially the middle dose group (P<0.01);the efforts of MDA reduction in the middle dose group is superior to the traditional Sheng-mai Capsule(P<0.01);CK,LDH enzyme activity were significantly decreased in Heart-Qi Deficiency mice,the reduction of LDH is superior to the Traditional Sheng-mai Capsule (P<0.05).
(2)the viscera index in different dose groups of Expanded Sheng-mai Capsule were all higher than control group,the thymus index、spleen index and renal index of middle dose group were obviously superior to that of control group (P<0.01),the liver index was higher than control group (P<0.05).The high dose group and middle dose group could significantly raise cell proliferative responses of immunosuppression in mice (P<0.01);DNA content in different dose groups were much higher than model group (P<0.01),the high dose group was higher than Traditional Sheng-mai Capsule.
(3) Expanded Sheng-mai Capsule and Traditional Sheng-mai Capsule could both prolong the clipping trachea time and disappearance time of ECG (P<0.01),different dose groups of Expanded Sheng-mai Capsule were all better than Traditional Sheng-mai Capsule (P<0.05),the efforts of high dose group was much better than the middle dose group and low dose group.The high dose group and middle dose group of Expanded Sheng-mai Capsule could obviously prolong the survival time in closed hypoxia tolerance of mice (P<0.05),and were much better than that of Traditional Sheng-mai Capsule (P<0.05).
(4) Expanded Shengmai capsules could obviously improve the symptoms of heart failure in rats,decrease LVMI,reduce its organization pathological injury.Expanded Sheng-mai Capsules treatment can obviously increase±dp/dtmax and LVSP,and decrease LVEDP obviously.
Conelusion:Expanded Sheng-mai Capsules could protect Heart-Qi Deficiency in mice,it may play a role in protect and recover change in immune organs and main organs、the changes of spleen function and bone marrow injury caused by cyclophosphamide,the mean survival time of mice was prolonged,decrease myocardial oxygen consumption.It has remarkable effect to myocardium against hypoxia.Expanded Sheng-mai Capsules may improve CHF systolic and diastolic function of the left ventricular,and has the efficacy of anti-CHF.The efficacy of Expanded Sheng-mai Capsules is better than Traditional Sheng-mai Capsule.
引文
[1]Kim HS, Hwang SL, Oh S, et al.Ginsenoside Re and Rg1diffferentially Modulate NMDA receptor subunit mRNA levels after intracerebroven-tricular Infusion in rats.Neurochemical Research,2000,25:1149-1154.
[2]Kim HS, Hwang SL, Oh S, et al.Chang of [3H] MK801, [3H] muscimal and [3H] flunitrazepamn binding in rat brain by the prolonged ventric-ular infusion of ginsenoside Re and Rg1.Pharmacological Resea rch,2001,43:473-479.
[3]Hasegawa H, Lee Ks, Nagaoga T, et al.Pharmacokinetics of ginsenoside deglycosylated by intestinal bacterial and its transformation to biologic-ally active fatty esters [J]. Biol. Pharm.Bull.2003,23 (3):298-304.
[4]Suda K, Murakami K, Muarata J, et al.An intestinal bacterial metabolite of ginseng protopanaxadiol saponins inhibits tumot induced neovas cularization [J].Trad.Med.2000 (17):144-145.
[5]Hasegawa H, Uchiyama M.Antimetasatic efficacy of orally, administered girtsenoside Rbl in dependence no intestinal bacterial hydrolyzing potential and significance of treatment with an active hacterial metabolite [J]. Planta.Med. 1998 (64):696-700.
[6]Shen LH, Zhang J T. Ginsenoside Rg1 promotes proliferation of hippoca-mpal progenitor cells.Neurol Res 2004,26 (4):422-428.
[7]Rudakewich M, Ba F, Benishin CG. Neurotrophic and neuroprotective actions of ginseng-osides Rb (1) and Rg (1).Planta Med,2001,67 (6):533-537.
[8]Tsai CC, Lu MC, Chen YS, et al. Locally administered never growth factor suppresses ginsenoside Rbl-enhanced peripheral nerve regene-ration.Am J Chin Med,2003,31 (5):665-673.
[9]Kim S, Ahn K, Oh TH, et al.Inhibitory effect of ginsenosides on NMDA receptormediated signal in rat hippocampal neurons.Biochemical & Research Communications,2003,31 (5):665-673.
[10]易进海.麦冬研究进展[J].华西药学杂志,1993,8(1)：32-38.
[11]Tada A, Shoji J. Studies on the Constituents of Ophiopogonis Tuber. Ⅱ.On the Structure of Ophiopogonin B. Chem. Pham.Bull.1972,20 (8):1729-1934.
[12]Tada A, Kobayashi M, Shoji J. Studies on the Costituents of Ophiopog-onis Tuber.Ⅲ.On the Structure of Ophiopogonin D.Chem.Pharm. Bull.1973,21 (1):308-311.
[13]Watanabe Y, Sanada S, Tada A, et al.Studies on the Constituents of Oph-iopogonins Tuber. IV. On the Structure of OphiopogoninA, B, C, C, and D.Chem.Pharm.Bull.1977,25 (11):3049-3055.
[14]杨清林,顾月翠,姜荣兰.川麦冬及其炮制品总黄酮和微量元素的比较[J].华西药学杂志,1995,10(2)：77-80.
[15]Cheng ZH, Wu T, Yu BY. Steroidal glycosides from tubers of ophiopo-gon japonicus[J] J Asian Nat Prod Res,2006,8:555-559.
[16]金田宣,中西裕幸,仓石忠幸,等.麦门冬(中国产)的成分研究[J]. Yakugaku Zasshi,1983,103 (11):1133-1139.
[17]Fang XC, Yu BY, An DK, et al. Application of pyrolysis-high-reso-lution gas chromatography-pattern recognition to the identify-cation of the Chinese traditional medicine Mai-dong [J]. JChromat-o gr,1990, 514:287-292.
[18]Yu BY, Xu GJ, et al.Comparative studies on the constituents of ophi-opogonis tuber and its congeners. VI[J].Chem Pharm Bull,1990, 38 (7):1931-1935.
[19]程金波,卫洪昌,沈章,等.麦冬提取物抗犬心肌缺血的药效实验[J].中国病理生理杂志,1989,14(6)：359-360.
[20]顾双林,纪克.麦冬对实验性心肌梗塞及心肌缺养时亚微结构的影响[J].上海中医药杂志,1983,(7)：44-45.
[21]陈敏,朱寄天,等.麦冬总皂苷抗心律失常作用及其电生理特性[J].中国药理学报,1990,11(2)：161-165.
[22]宋晓亮,高广猷,叶丽红.山麦冬总皂苷对实验性心肌缺血的影响[J].中国药理学通报,1996,12(2)：329-332.
[23]Wu FH, Cao JS, Jiang JY, et al. Ruscogenin glycoside (Lm-3) isolated fromLiriope muscariimproves livers injury by dysfunctioning liver-in-filtrating lymphocytes[J].J Pharm Pharmcol,2001,53:681-688.
[24]烫军,钱华,黄琦,等.麦冬多糖平喘和抗过敏作用研究[J].中国现代应用药学杂志,1999,16(2)：16-19.
[25]刘冰,武广恒.麦冬对镉所致遗传损伤的抑制作用研究[J].长春中医学院学报,1998,14(4)：53.
[26]Liu JL, Chen T, Yu BY, et al. Ruscogenin glycoside (Lm-3) isolated from Liriope muscariinhibits lymphocyte adhesion to extracellu-lar matrix[J].JPharm Pharmacol,2002,54:959-966.
[27]张卫星,王乃华.麦冬多糖对氧嘧啶糖尿病小鼠高血糖的降低作用[J].中草药,1993,24(1)：30-31.
[28]Kako M, Miura T, UsamiM, et al.Hypoglycemic effect of the rhi2 zomes of ophiopogonis tuber in normal and diabetic mice [J].Biol Phar m Bull,1995, 18 (2):785-787.
[29]黄琦,等.麦冬多糖对2型糖尿病血糖及胰岛素抵抗的影响[J].浙江中西医结合杂志,1992,12(2)：81-82.
[30]王智杰,苟小林.麦冬降血糖作用的药效学研究[J].中医药学刊,2003,21(6)：898-899.
[31]Kou JP, Sun Y, Lin YW, et al. Anti-inflammatory activities of aqueous extract fromRadix Ophiopogon japonicusand its two con-stituents [J]. Biol Pharm Bull,2005,28:1234-1238.
[32]余伯阳,殷霞.麦冬多糖的免疫活性研究.中国药科大学学报,1991,22,(2)：286-288.
[33]陶站华,白书阁,白晶.麦冬对D半乳糖衰老模型大鼠的抗衰老作用研究[J].黑龙江医药科学,1999,22(4)：36237.
[34]莫正纪,江光池,冉兰,等.麦冬有效成分的药理研究[J].华西药学杂志,1991,6(1) ：13-15.
[35]徐慧字,于刚,等.中药麦冬对大鼠红细胞免疫功能及抗衰老作用的研究[J].中医药学报,2001,29(1)：46-47.
[36]Song ZY. Modern Researches of Traditional Chinese Medicines[M].Beijing: Peking Medical College andPeking Union Medical College United Press,1995
[37]KEMQ.Physical and pharmacological properties of efficient components in traditional Chinese medincines[M]. Changsha:Human'Science and Technology Publishing House.1982:541.
[38]周英,杨俊山,王立为.五味子科植物三帖成分[J].中国药学杂志,2003,38(2)：81-83.
[39]薛梅,周静.五味子多糖的提取及含量测定[J].陕西中医,2003,24(3)：267-268.
[40]戴好富,周俊,彭再刚,等.北五味子水溶性化学成分[J].天然产物研究与开发,2000,13(1)：24-26.
[41]李爱民,王英范,李昌禹,等.北五味子果实成熟期营养成分变化的研究[J].特产研究,2004,20(3)：8-10.
[42]李海涛,胡刚.五味子醇甲抑制6-羟基多巴胺诱导PC12细胞凋亡的研究[J].南京中医药大学学报,2004,20(2)：961.
[43]李莉,刘耕陶.五味子酚和丹酚酸A对H202引起大鼠脑神经细胞凋亡的保护作用[J].中国药理学与毒理学杂志,1996,10(2)：921.
[44]许志奇,彭国瑞,曾祥国,等.红参、五味子防治小鼠慢性支气管炎的实验研究[J].中药药理与临床,1992,8(6)：281.
[45]黄玲,张捷平,陈华.五味子多糖对S180荷瘤小鼠抑瘤作用的研究[J].福建中医学院学报,2003,13(3)：22.
[46]Miyamoto K, Hiramatsu K, Ohtaki Y, et al. Effects of Gomisin A on the Promotor Action and Serum Bile Acid Concentration in Hepatocarcino genesis Induced by 3'-methyl-4-dimethylamino-azobenzene [J]. Biol PharmBull, 1995,18 (10):1443-1445.
[47]Chiu PY, Mak DHF, Poon MKT, et al. In Vivo Antioxidant Action of a Lignan-enriched Extract ofSchisandra Fruit and an Anthraquinone-containing Extract of Polygonum Root in Comparison with chisand rinB and Emodin [J]. Planta Medica,2002 (English),68 (11):951-956.
[48]Yi-Feng Wu, Ming-Fu Cao, Yan-Ping Gao, et al.Down-modulation of heat shock protein 70 and up-modulation of caspase-3 during schisan-drin B-induced apoptosis in human hepatoma SMMC-7721 cell[J].World J Gastroenterol, 2004,10 (20):2944.
[49]姜怡.《生脉膨化胶囊制备工艺及质量标准研究》.西南交通大学硕士学位论文,2008：44.
[50]王汉森,马沛然.参麦注射液对阿霉素中毒心肌细胞脂质过氧化和钙超载的影响[J].安徽中医学院学报,2001,20(3)：38-40.
[51]Sazuka Y, Tanizawa H, Takino Y. Effect of adriamycin on DNA, RNA and protein biosynthesis in mouse issues, in connection with its cardiotoxity. Jpn J Cancer Res,1992,80:1000
[52]陈元美,杨菊贤,等.生脉注射液与黄芪注射液对冠心病伴左心功能不全的疗效比较[J].中国新药与临床杂志,1998,17(3)：154.
[53]檀金川,谢惠芳,齐丽娟,等.生脉液治疗心肌炎30例[J].河北中医,1995,17(4)：47.
[54]郭世彪,孙敬田,荣文.生脉注射液治疗糖尿病45例疗效观察[J].实用中西医结合杂志,1998,11(12)：1087.
[55]方宗君,蒋浩明,王丽华.生脉注射液对慢性阻塞性肺病患者呼吸功能的疗效观察[J].中国中西医结合杂志,1998,18(9)：520.
[56]白玉莲.生脉散静滴治疗病窦综合征50例临床报告[J].中医药研究,1995,(1)：27.
[57]邱秉新,邱森山.生脉饮治疗脑功能轻微障碍综合征[J].中医杂志,1992,33(1)：32.
[58]邓洁红,曹乐平.螺杆挤压机在膨化食品生产中的应用[J].包装与食品机械,2004,22(5)：30-32.
[59]蒋亚生.膨化技术在中药炮制中的应用[J].时珍国医国药,1996,7(4)：35.
[60]吴建华,催九成.山药炮制方法初探[J].陕西中医学院学报,2000,23(4)：49-50.
[61]王盛民,张瑛,侯新江等.膨化加工对人参改善小鼠学习记忆能力的影响[J].陕西中医,2006,27(6)：723-724.
[62]王盛民,张瑛,侯新江等.膨化生脉饮对环磷酰胺所致免疫抑制小鼠免疫功能的影响[J].吉林中医药,2006,26(4)：58-59.
[63]张翠英.《人参膨化炮制及膨化饮片的质量研究》.西南交通大学硕士论文, 2007：35.
[64]郭霭春主编.《黄帝内经素问语译》.人民卫生出版社出版.1992,第1版(上册).《水热穴论篇第六十一》：339； 《逆调论篇第三十四》：208.
[65]郑艺文编.《金匿要略浅释》.湖南科学技术出版社出版.1983,第1版.《痰饮咳嗽病脉证治第一》：170-1； 《痰饮咳嗽病脉证治第十二》：177-8.
[66]夏之秋校注.明·张介宾著《景一岳全书》.中国中医药出版社出版.1994,第1版.《水肿论治》：271.
[67]李南夷,邓铁涛,陈镜合.充血性心力衰竭中医病名小议.新中医,1994,2：7-9.
[68]程丑夫,张炜宁.心衰的中医病证归属浅析.山东中医药人学学报,1998,22(2)：107-8.
[69]何建成,曹雪滨.浅谈充血性心力衰竭中医药治疗.甘肃中医,1999,12(4)：10-11.
[70]毛春燕.中医对充血性心力衰竭的认识及治疗对策.河北中医,2002,24(11)：823-4.
[71]吴勉华.充血.性心力衰竭中医病机探讨.南京中医药大学学报(自然科学版),2001,17(4)：206-9.
[72]蔡辉,胡婉英.中医药治疗充血性心力衰竭的理论研究概况.河北中医药学报,2000,15(3)：41-3.
[73]郭毅.试论心衰及其治疗体会.四川中医,1996,14(8)：6.
[74]董泉珍.中西医结合治疗心力衰竭的探讨.中国中西医结合杂志,1996：16(12)：745-8.
[75]成启予,方祝元.浅谈充血性心力衰竭的中医诊断及其证治.南京中医学院学报,1994,10(2)：23-4.
[76]霍根红.谈气、血、水相关理论与心力衰竭.河南中医药学刊,1995,10(4)：8-9.
[77]霍根红.试论充血性心力衰竭的中医病理实质.河南中医,1996,16(5)：274-66.
[78]杜惠芳,杨加禄,郭素英.慢性心衰与痰之关系初探.河南中医药学刊,1998,13(3)：34-6.
[79]林齐鸣.试论心与水液代谢的关系.四川中医,1996,14(11)：1-2.
[80]李南夷.邓铁涛教授治疗心衰的思路与方法.新中医,1995,10：6-8.
[81]鲁端.临床心肌缺血与心律失常.医师进修杂志(内科版)2004,27(1)：52-54.
[82]叶任高,陆再英主编.《内科学》(第六版)北京,人民卫生出版社.2004：29.7
[83]崔颖,张婷,张喜云,心肌缺血治疗药物的研究进展.解放军药学学报,2002,18(6)：347-350
[84]张东,管宏钟.心肌缺血／再灌注损伤的中西医结合病理研究.中医杂志2005,46(9)：702-704.
[85]黄海霞,莫晓燕.中药对心肌细胞损伤的保护作用中草药,2003,34(12)：1150-1152.
[86]RobertB.Jennings, Jutta Schaper, MaryL. hill, etal. Effect of reperfusion late in the phase ofreversibleis chemic injury.CirR.es,1985,56:262.
[87]Mauser M., Hoffineister HM., Nienaber C, etal. In influence of ribose, adenosine, and"AICAR" on the rate of myocardia, adenosine triphosphatesyn-thesis during reperfusion after coronary arteryocclu-sion in the dog.CirRes,1985,56:22.
[88]FerrariR. CeconiC, CurelloS. etal. Myocardial damage during ischemia and reperfusion.European Heart Journal,1993,14 (supplG):25.
[89]Mervyn B. Forman, RenuVirmani, DavidW.Puett, etal. Mechanism and therapy of myocardial reperfu-sioninjury.Circulation,1990,81 (supplIV):IV69-IV78.
[90]龚非力.现代免疫学[M].北京：科学出版社,2000,1：273.
[91]沈玉清.临床免疫学[M].吉林：吉林科学出版社,1987,1：477,430,479,481.
[92]许得盛,沈自尹,土文健等.右归饮、四君子汤、桃红四物汤调节肾虚、脾虚、血瘀证患者免疫功能的观察[J].中国中西医结合杂志,1999；19(12)：714.
[93]贺新怀,席孝贤.中医药免疫学[M].北京：人民军医出版社,2002,1：24.
[94]徐晓玉,刘全让,陈静等.益气免疫冲剂治疗气虚证慢性阻塞性肺病72例观察[J].中国中西医结合杂志,1996；16(2)：8183.
[95]傅芳.中医免疫思想及成就[J].中医杂志,1984； (8)：72.
[96]钱农,杨吉成.人参多糖及其皂若等5种中药提取物促诱生人干扰素的研究[J].苏州医学院学报,1997；17(1)：3132.
[2]Kim HS, Hwang SL, Oh S, et al.Chang of [3H] MK801, [3H] muscimal and [3H] flunitrazepamn binding in rat brain by the prolonged ventric-ular infusion of ginsenoside Re and Rg1.Pharmacological Resea rch,2001,43:473-479.
[3]Hasegawa H, Lee Ks, Nagaoga T, et al.Pharmacokinetics of ginsenoside deglycosylated by intestinal bacterial and its transformation to biologic-ally active fatty esters [J]. Biol. Pharm.Bull.2003,23 (3):298-304.
[4]Suda K, Murakami K, Muarata J, et al.An intestinal bacterial metabolite of ginseng protopanaxadiol saponins inhibits tumot induced neovas cularization [J].Trad.Med.2000 (17):144-145.
[5]Hasegawa H, Uchiyama M.Antimetasatic efficacy of orally, administered girtsenoside Rbl in dependence no intestinal bacterial hydrolyzing potential and significance of treatment with an active hacterial metabolite [J]. Planta.Med. 1998 (64):696-700.
[6]Shen LH, Zhang J T. Ginsenoside Rg1 promotes proliferation of hippoca-mpal progenitor cells.Neurol Res 2004,26 (4):422-428.
[7]Rudakewich M, Ba F, Benishin CG. Neurotrophic and neuroprotective actions of ginseng-osides Rb (1) and Rg (1).Planta Med,2001,67 (6):533-537.
[8]Tsai CC, Lu MC, Chen YS, et al. Locally administered never growth factor suppresses ginsenoside Rbl-enhanced peripheral nerve regene-ration.Am J Chin Med,2003,31 (5):665-673.
[9]Kim S, Ahn K, Oh TH, et al.Inhibitory effect of ginsenosides on NMDA receptormediated signal in rat hippocampal neurons.Biochemical & Research Communications,2003,31 (5):665-673.
[10]易进海.麦冬研究进展[J].华西药学杂志,1993,8(1)：32-38.
[11]Tada A, Shoji J. Studies on the Constituents of Ophiopogonis Tuber. Ⅱ.On the Structure of Ophiopogonin B. Chem. Pham.Bull.1972,20 (8):1729-1934.
[12]Tada A, Kobayashi M, Shoji J. Studies on the Costituents of Ophiopog-onis Tuber.Ⅲ.On the Structure of Ophiopogonin D.Chem.Pharm. Bull.1973,21 (1):308-311.
[13]Watanabe Y, Sanada S, Tada A, et al.Studies on the Constituents of Oph-iopogonins Tuber. IV. On the Structure of OphiopogoninA, B, C, C, and D.Chem.Pharm.Bull.1977,25 (11):3049-3055.
[14]杨清林,顾月翠,姜荣兰.川麦冬及其炮制品总黄酮和微量元素的比较[J].华西药学杂志,1995,10(2)：77-80.
[15]Cheng ZH, Wu T, Yu BY. Steroidal glycosides from tubers of ophiopo-gon japonicus[J] J Asian Nat Prod Res,2006,8:555-559.
[16]金田宣,中西裕幸,仓石忠幸,等.麦门冬(中国产)的成分研究[J]. Yakugaku Zasshi,1983,103 (11):1133-1139.
[17]Fang XC, Yu BY, An DK, et al. Application of pyrolysis-high-reso-lution gas chromatography-pattern recognition to the identify-cation of the Chinese traditional medicine Mai-dong [J]. JChromat-o gr,1990, 514:287-292.
[18]Yu BY, Xu GJ, et al.Comparative studies on the constituents of ophi-opogonis tuber and its congeners. VI[J].Chem Pharm Bull,1990, 38 (7):1931-1935.
[19]程金波,卫洪昌,沈章,等.麦冬提取物抗犬心肌缺血的药效实验[J].中国病理生理杂志,1989,14(6)：359-360.
[20]顾双林,纪克.麦冬对实验性心肌梗塞及心肌缺养时亚微结构的影响[J].上海中医药杂志,1983,(7)：44-45.
[21]陈敏,朱寄天,等.麦冬总皂苷抗心律失常作用及其电生理特性[J].中国药理学报,1990,11(2)：161-165.
[22]宋晓亮,高广猷,叶丽红.山麦冬总皂苷对实验性心肌缺血的影响[J].中国药理学通报,1996,12(2)：329-332.
[23]Wu FH, Cao JS, Jiang JY, et al. Ruscogenin glycoside (Lm-3) isolated fromLiriope muscariimproves livers injury by dysfunctioning liver-in-filtrating lymphocytes[J].J Pharm Pharmcol,2001,53:681-688.
[24]烫军,钱华,黄琦,等.麦冬多糖平喘和抗过敏作用研究[J].中国现代应用药学杂志,1999,16(2)：16-19.
[25]刘冰,武广恒.麦冬对镉所致遗传损伤的抑制作用研究[J].长春中医学院学报,1998,14(4)：53.
[26]Liu JL, Chen T, Yu BY, et al. Ruscogenin glycoside (Lm-3) isolated from Liriope muscariinhibits lymphocyte adhesion to extracellu-lar matrix[J].JPharm Pharmacol,2002,54:959-966.
[27]张卫星,王乃华.麦冬多糖对氧嘧啶糖尿病小鼠高血糖的降低作用[J].中草药,1993,24(1)：30-31.
[28]Kako M, Miura T, UsamiM, et al.Hypoglycemic effect of the rhi2 zomes of ophiopogonis tuber in normal and diabetic mice [J].Biol Phar m Bull,1995, 18 (2):785-787.
[29]黄琦,等.麦冬多糖对2型糖尿病血糖及胰岛素抵抗的影响[J].浙江中西医结合杂志,1992,12(2)：81-82.
[30]王智杰,苟小林.麦冬降血糖作用的药效学研究[J].中医药学刊,2003,21(6)：898-899.
[31]Kou JP, Sun Y, Lin YW, et al. Anti-inflammatory activities of aqueous extract fromRadix Ophiopogon japonicusand its two con-stituents [J]. Biol Pharm Bull,2005,28:1234-1238.
[32]余伯阳,殷霞.麦冬多糖的免疫活性研究.中国药科大学学报,1991,22,(2)：286-288.
[33]陶站华,白书阁,白晶.麦冬对D半乳糖衰老模型大鼠的抗衰老作用研究[J].黑龙江医药科学,1999,22(4)：36237.
[34]莫正纪,江光池,冉兰,等.麦冬有效成分的药理研究[J].华西药学杂志,1991,6(1) ：13-15.
[35]徐慧字,于刚,等.中药麦冬对大鼠红细胞免疫功能及抗衰老作用的研究[J].中医药学报,2001,29(1)：46-47.
[36]Song ZY. Modern Researches of Traditional Chinese Medicines[M].Beijing: Peking Medical College andPeking Union Medical College United Press,1995
[37]KEMQ.Physical and pharmacological properties of efficient components in traditional Chinese medincines[M]. Changsha:Human'Science and Technology Publishing House.1982:541.
[38]周英,杨俊山,王立为.五味子科植物三帖成分[J].中国药学杂志,2003,38(2)：81-83.
[39]薛梅,周静.五味子多糖的提取及含量测定[J].陕西中医,2003,24(3)：267-268.
[40]戴好富,周俊,彭再刚,等.北五味子水溶性化学成分[J].天然产物研究与开发,2000,13(1)：24-26.
[41]李爱民,王英范,李昌禹,等.北五味子果实成熟期营养成分变化的研究[J].特产研究,2004,20(3)：8-10.
[42]李海涛,胡刚.五味子醇甲抑制6-羟基多巴胺诱导PC12细胞凋亡的研究[J].南京中医药大学学报,2004,20(2)：961.
[43]李莉,刘耕陶.五味子酚和丹酚酸A对H202引起大鼠脑神经细胞凋亡的保护作用[J].中国药理学与毒理学杂志,1996,10(2)：921.
[44]许志奇,彭国瑞,曾祥国,等.红参、五味子防治小鼠慢性支气管炎的实验研究[J].中药药理与临床,1992,8(6)：281.
[45]黄玲,张捷平,陈华.五味子多糖对S180荷瘤小鼠抑瘤作用的研究[J].福建中医学院学报,2003,13(3)：22.
[46]Miyamoto K, Hiramatsu K, Ohtaki Y, et al. Effects of Gomisin A on the Promotor Action and Serum Bile Acid Concentration in Hepatocarcino genesis Induced by 3'-methyl-4-dimethylamino-azobenzene [J]. Biol PharmBull, 1995,18 (10):1443-1445.
[47]Chiu PY, Mak DHF, Poon MKT, et al. In Vivo Antioxidant Action of a Lignan-enriched Extract ofSchisandra Fruit and an Anthraquinone-containing Extract of Polygonum Root in Comparison with chisand rinB and Emodin [J]. Planta Medica,2002 (English),68 (11):951-956.
[48]Yi-Feng Wu, Ming-Fu Cao, Yan-Ping Gao, et al.Down-modulation of heat shock protein 70 and up-modulation of caspase-3 during schisan-drin B-induced apoptosis in human hepatoma SMMC-7721 cell[J].World J Gastroenterol, 2004,10 (20):2944.
[49]姜怡.《生脉膨化胶囊制备工艺及质量标准研究》.西南交通大学硕士学位论文,2008：44.
[50]王汉森,马沛然.参麦注射液对阿霉素中毒心肌细胞脂质过氧化和钙超载的影响[J].安徽中医学院学报,2001,20(3)：38-40.
[51]Sazuka Y, Tanizawa H, Takino Y. Effect of adriamycin on DNA, RNA and protein biosynthesis in mouse issues, in connection with its cardiotoxity. Jpn J Cancer Res,1992,80:1000
[52]陈元美,杨菊贤,等.生脉注射液与黄芪注射液对冠心病伴左心功能不全的疗效比较[J].中国新药与临床杂志,1998,17(3)：154.
[53]檀金川,谢惠芳,齐丽娟,等.生脉液治疗心肌炎30例[J].河北中医,1995,17(4)：47.
[54]郭世彪,孙敬田,荣文.生脉注射液治疗糖尿病45例疗效观察[J].实用中西医结合杂志,1998,11(12)：1087.
[55]方宗君,蒋浩明,王丽华.生脉注射液对慢性阻塞性肺病患者呼吸功能的疗效观察[J].中国中西医结合杂志,1998,18(9)：520.
[56]白玉莲.生脉散静滴治疗病窦综合征50例临床报告[J].中医药研究,1995,(1)：27.
[57]邱秉新,邱森山.生脉饮治疗脑功能轻微障碍综合征[J].中医杂志,1992,33(1)：32.
[58]邓洁红,曹乐平.螺杆挤压机在膨化食品生产中的应用[J].包装与食品机械,2004,22(5)：30-32.
[59]蒋亚生.膨化技术在中药炮制中的应用[J].时珍国医国药,1996,7(4)：35.
[60]吴建华,催九成.山药炮制方法初探[J].陕西中医学院学报,2000,23(4)：49-50.
[61]王盛民,张瑛,侯新江等.膨化加工对人参改善小鼠学习记忆能力的影响[J].陕西中医,2006,27(6)：723-724.
[62]王盛民,张瑛,侯新江等.膨化生脉饮对环磷酰胺所致免疫抑制小鼠免疫功能的影响[J].吉林中医药,2006,26(4)：58-59.
[63]张翠英.《人参膨化炮制及膨化饮片的质量研究》.西南交通大学硕士论文, 2007：35.
[64]郭霭春主编.《黄帝内经素问语译》.人民卫生出版社出版.1992,第1版(上册).《水热穴论篇第六十一》：339； 《逆调论篇第三十四》：208.
[65]郑艺文编.《金匿要略浅释》.湖南科学技术出版社出版.1983,第1版.《痰饮咳嗽病脉证治第一》：170-1； 《痰饮咳嗽病脉证治第十二》：177-8.
[66]夏之秋校注.明·张介宾著《景一岳全书》.中国中医药出版社出版.1994,第1版.《水肿论治》：271.
[67]李南夷,邓铁涛,陈镜合.充血性心力衰竭中医病名小议.新中医,1994,2：7-9.
[68]程丑夫,张炜宁.心衰的中医病证归属浅析.山东中医药人学学报,1998,22(2)：107-8.
[69]何建成,曹雪滨.浅谈充血性心力衰竭中医药治疗.甘肃中医,1999,12(4)：10-11.
[70]毛春燕.中医对充血性心力衰竭的认识及治疗对策.河北中医,2002,24(11)：823-4.
[71]吴勉华.充血.性心力衰竭中医病机探讨.南京中医药大学学报(自然科学版),2001,17(4)：206-9.
[72]蔡辉,胡婉英.中医药治疗充血性心力衰竭的理论研究概况.河北中医药学报,2000,15(3)：41-3.
[73]郭毅.试论心衰及其治疗体会.四川中医,1996,14(8)：6.
[74]董泉珍.中西医结合治疗心力衰竭的探讨.中国中西医结合杂志,1996：16(12)：745-8.
[75]成启予,方祝元.浅谈充血性心力衰竭的中医诊断及其证治.南京中医学院学报,1994,10(2)：23-4.
[76]霍根红.谈气、血、水相关理论与心力衰竭.河南中医药学刊,1995,10(4)：8-9.
[77]霍根红.试论充血性心力衰竭的中医病理实质.河南中医,1996,16(5)：274-66.
[78]杜惠芳,杨加禄,郭素英.慢性心衰与痰之关系初探.河南中医药学刊,1998,13(3)：34-6.
[79]林齐鸣.试论心与水液代谢的关系.四川中医,1996,14(11)：1-2.
[80]李南夷.邓铁涛教授治疗心衰的思路与方法.新中医,1995,10：6-8.
[81]鲁端.临床心肌缺血与心律失常.医师进修杂志(内科版)2004,27(1)：52-54.
[82]叶任高,陆再英主编.《内科学》(第六版)北京,人民卫生出版社.2004：29.7
[83]崔颖,张婷,张喜云,心肌缺血治疗药物的研究进展.解放军药学学报,2002,18(6)：347-350
[84]张东,管宏钟.心肌缺血／再灌注损伤的中西医结合病理研究.中医杂志2005,46(9)：702-704.
[85]黄海霞,莫晓燕.中药对心肌细胞损伤的保护作用中草药,2003,34(12)：1150-1152.
[86]RobertB.Jennings, Jutta Schaper, MaryL. hill, etal. Effect of reperfusion late in the phase ofreversibleis chemic injury.CirR.es,1985,56:262.
[87]Mauser M., Hoffineister HM., Nienaber C, etal. In influence of ribose, adenosine, and"AICAR" on the rate of myocardia, adenosine triphosphatesyn-thesis during reperfusion after coronary arteryocclu-sion in the dog.CirRes,1985,56:22.
[88]FerrariR. CeconiC, CurelloS. etal. Myocardial damage during ischemia and reperfusion.European Heart Journal,1993,14 (supplG):25.
[89]Mervyn B. Forman, RenuVirmani, DavidW.Puett, etal. Mechanism and therapy of myocardial reperfu-sioninjury.Circulation,1990,81 (supplIV):IV69-IV78.
[90]龚非力.现代免疫学[M].北京：科学出版社,2000,1：273.
[91]沈玉清.临床免疫学[M].吉林：吉林科学出版社,1987,1：477,430,479,481.
[92]许得盛,沈自尹,土文健等.右归饮、四君子汤、桃红四物汤调节肾虚、脾虚、血瘀证患者免疫功能的观察[J].中国中西医结合杂志,1999；19(12)：714.
[93]贺新怀,席孝贤.中医药免疫学[M].北京：人民军医出版社,2002,1：24.
[94]徐晓玉,刘全让,陈静等.益气免疫冲剂治疗气虚证慢性阻塞性肺病72例观察[J].中国中西医结合杂志,1996；16(2)：8183.
[95]傅芳.中医免疫思想及成就[J].中医杂志,1984； (8)：72.
[96]钱农,杨吉成.人参多糖及其皂若等5种中药提取物促诱生人干扰素的研究[J].苏州医学院学报,1997；17(1)：3132.